Abstract: The present disclosure relates to a composition that includes a sequestering material capable of binding a target material, where the sequestering material includes a first component that includes at least one of a functional group, a molecule, an oligomer, or a polymer, and the target material includes at least one of an element, a chemical, and/or a compound. In some embodiments of the present disclosure, the element may include at least one element from at least one of Rows 4, 5, 6, and 7 of the Periodic Table and/or an inner transition metal.

Abstract: The present invention provides a process of solidifying a phosphoric ester-based flame retardant in which high-level purification is not required and stress load is not employed. In the process of solidifying a phosphoric ester-based flame retardant, a seed crystal is added at a temperature of not higher than 55° C. and at an amount of 1 to 50 parts by mass with respect to 100 parts by mass of a phosphoric ester compound in a molten state, which compound is represented by the following Formula (I): (wherein, R1 and R2 each independently represent a hydrogen atom or a methyl group; and n represents a number of 1 to 5). It is preferred that the amount of the phosphoric ester compound represented by the aforementioned Formula (I) wherein n is 1 be less than 90% by mass and that R1 and R2 be a hydrogen atom.

Abstract: A polymeric polyphosphite and copolymeric polyphosphite is described which contains a cycloaliphatic moiety, preferably cyclohexane dimethanol, in the polyphosphite backbone chain. Incorporation of the polymeric polyphosphite into synthetic polymers reduces the yellowness index of any polymer into which the polymeric polyphosphite additive has been added, as well as increased hydrolytic stability as well as increased resistance to migration in food packaging.

Abstract: A process for the catalyzed electrochemical reduction of carbon dioxide wherein a metal organic framework comprising metal ions and an organic ligand is used as a catalyst and novel metal organic frameworks based on bisphosphonic acids.

Abstract: An alkylphenol-free colorless liquid copolymeric polyphosphite is described of generic formula: wherein each R1, R2, R3, R4 and R5 can be the same or different and independently selected from the group consisting of C12-20 alkyl, C12-22 alkenyl, C12-40 cycloalkyl, C12-40-cycloalkenyl, C12-20 alkyl glycol ethers and A-OH and B—OH as an end-capping groups; each A and B are different and independently selected from the group consisting of C2-40 alkylene, C7-40 cycloalkylene, C3-20 alkyl glycol ethers, C3-40 alkyl lactone, and —R7—N(R8)—R9—; wherein R7, R8 and R9 are independently selected from the group C1-20 alkyl, C2-22 alkenyl, C6-40 cycloalkyl, C7-40 cycloalkylene and H; m and n are integral values ranging from 1 to 100 inclusive, with the proviso that when —O-A or —O—B are C3-20 alkyl glycol ethers, x or y is an integral value no less than 7; x and y are integral values ranging from 1 to 1,000 wherein x+y sum to at least 3; and further wherein no more than two of R1, R2, R3, R4 and R5 are terminated w

Abstract: Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.

Abstract: A polymeric polyphosphite and copolymeric polyphosphite is described which contains a cycloaliphatic moiety, preferably cyclohexane dimethanol, in the polyphosphite backbone chain.

Abstract: An alkylphenol-free liquid polymeric phosphite is described of general Structure IV illustrated below wherein each R1, R2, R3 and R4 can be the same or different and independently selected from the group consisting of C1-20 alkyl, C3-22 alkenyl, C6-40 cycloalkyl, C7-40 cycloalkylene, C1-20 methoxy alkyl glycol ethers, C1-20 alkyl glycol ethers, and or Y—OH; Y is selected from the group consisting of C2-40 alkylene, C2-40 alkyl lactone, —R7—N(R8)—R9—, wherein R7, R8 and R9 are independently selected from the group previously defined for R1, R2, R3 and R4, now further including H; m is an integral value ranging from 2 to 100 inclusive; and x is an integral value ranging from 1 to 1,000. The alkylphenol-free liquid polymeric phosphite is useful in reducing phosphite migration within polymers.

Abstract: An alkylphenol-free liquid polymeric polyphosphite is described of general Structure IV illustrated below wherein each R1, R2, R3 and R4 can be the same or different and independently selected from the group consisting of C1-20 alkyl, C2-22 alkenyl, C6-40 cycloalkyl, C7-40 cycloalkylene, C3-20 methoxy alkyl glycol ethers, C3-20 alkyl glycol ethers, and or Y—OH; Y is selected from the group consisting of C2-40 alkylene, C2-40 alkyl lactone, —R7—N(R8)—R9—, wherein R7, R8 and R9 are independently selected from the group previously defined for R1, R2, R3 and R4, now further including H; m is an integral value ranging from 2 to 100 inclusive; and x is an integral value ranging from 1 to 1,000 and further in which by controlling a molar ratio of reactants, the number of terminal hydroxyl groups is minimized. The alkylphenol-free liquid polymeric phosphite is useful in reducing phosphite migration within polymers.

Abstract: The present invention relates to phenol-free phosphites and preparation thereof. The phenol-free phosphites are obtained by reacting biphenol, and phosphorous derivatives with higher aliphatic alcohol via condensation and trans-esterification. The phenol-free phosphites of the present invention can be used as a heat stabilizer for resin so as to enhance the heat resistance of the resin during processing at high temperatures.

Abstract: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.

Abstract: The invention concerns the production of salts or chelates of methyl donors, in particular S-adenosyl-L-methionine or SAMe and betaine or N,N,N-trimethylglycine, with phytic acid or with phosphorylate inositol, possibly partially salified with metal cations, with the formation of stable, totally natural, compounds having a biological activity typical of the starting methyl donors and also combined with, and enhanced by, the biological activity typical of phytic acid or of inositol. The invention also concerns nutraceutical, pharmaceutical, dietary, phytopharmaceutical or veterinary compositions comrising one or more salts or complexes of methyl donors with phytic acid or its derivatives and the method for the synthesis thereof.

Abstract: Mixtures of three types of linear, branched or cyclic phosphates are useful flame retardants, especially for thermoplastic resins or as functional additives in polymer matrices.

Abstract: The present invention relates to a method of producing a polymerizable phosphate containing at least one selected from polymerizable phosphates represented by formula (II), (III) or (IV) by a batch reaction, including a step of adding a compound represented by formula (I) into a mixture of a polymerizable phosphate reaction product containing at least one selected from polymerizable phosphates represented by formula (II), (III) or (IV), obtained by a pre-batch reaction, and phosphoric acid anhydride to react them: wherein R1 represents H or a C1-4 alkyl group, R2 represents a C2-6 alkylene group and n denotes an integer from 1 to 3.

Abstract: Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.

Abstract: The synthesis and biochemical utility of modified oligonucleotides containing diphosphodiester internucleotide linkages. The synthesis of these compounds was carried out using diphosphitylating reagents. Oligonucleotides containing diphosphate diester bridges wherein said oligonucleotides are synthesized via a solid-phase synthesis strategy to form modified oligonucleotides. Diphosphitylating, triphosphitylating, tetraphosphitylating, ?-triphosphitylating, bifunctional diphosphitylating, bifunctional triphosphitylating, and bifunctional tetraphosphitylating reagents wherein, the phosphorus atoms are linked together through oxygen, sulfur, amino, or methylene groups and/or are substituted with chlorine, diisopropylamine and cyanoethoxy groups.

Abstract: An alkylphenol-free liquid polymeric phosphite is described of general Structure IV illustrated below wherein each R1, R2, R3 and R4 can be the same or different and independently selected from the group consisting of C1-20 alkyl, C3-22 alkenyl, C6-40 cycloalkyl, C7-40 cycloalkylene, C1-20 methoxy alkyl glycol ethers, C1-20 alkyl glycol ethers, and or Y—OH; Y is selected from the group consisting of C2-40 alkylene, C2-40 alkyl lactone, —R7—N(R8)—R9—, wherein R7, R8 and R9 are independently selected from the group previously defined for R1, R2, R3 and R4, now further including H; m is an integral value ranging from 2 to 100 inclusive; and x is an integral value ranging from 1 to 1,000. The alkylphenol-free liquid polymeric phosphite is useful in reducing phosphite migration within polymers.

Abstract: A phosphorus flame-retardant composition characterized in that it comprises an aromatic diphosphate compound represented by the general formula (I): wherein R1 and R2 are, the same or different, a lower alkyl group, R3 and R4 are, the same or different, a hydrogen atom or a lower alkyl group, Y is a bonding arm, a —CH2—, —C(CH3)2—, —S—, —SO2?, —O—, —CO— or —N?N— group, k is 0 or 1, and m is an integer from 0 to 4, and it contains, as an impurity, a phosphorus compound having a hydroxyphenyl group represented by the general formula (II): wherein R1, R2, R3, R4, Y, k and m are as defined in the general formula (I), the content of the phosphorus compound being 1% by area or less as determined by gel permeation chromatography (GPC).

Abstract: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: The invention relates to a process for preparing ethylenedialkylphosphinic acids, ethylenedialkylphosphinic esters and ethylenedialkylphosphinic salts, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) in the presence of a catalyst A to give an alkylphosphonous acid, its salt or ester (II), b) the resultant alkylphosphonous acid, its salt or ester (II) is reacted with an acetylenic compound (V) in the presence of a catalyst B, to give the ethylenedialkylphosphinic acid derivative (III), where R1, R2, R3, R4, R5, R6, R11, R12, R13 and R14 are identical or different and independently of one another inter alia are H, C1-C18-alkyl, C6-C18-aryl, C6-C18-aralkyl, C6-C18-alkylaryl and X is H, C1-C18-alkyl, C6-C18-aryl, C6-C18-aralkyl, C6-C18-alkylaryl, Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K and/or a protonated nitrogen base, and the catalyst A comprises transition metals and/or transition-metal compounds and/or catalyst systems which are composed of

Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.

Abstract: New highly-effective non-halogen, low VOC, low fogging, and cost-effective oligomeric polyphosphonate flame retardants for flexible polyurethane foams as well as for other flame retardant applications are described. In addition, methods for the preparation and uses of such new highly effective flame retardants are described.

Abstract: This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.

Abstract: Disclosed are mixtures of oxyalkylene bridged bis- and tris-phosphite esters of formulae I and II where R is hydrogen or methyl, n and n? are independently an integer from 1 to 45 and R1, R2 and R3 are each independently hydrogen, straight or branched chain alkyl of 1 to 12 carbon atoms, phenylalkyl of 7 to 9 carbon atoms, phenylalkyl of 7 to 9 carbon atoms substituted on the phenyl ring by one to three straight or branched chain alkyl of 1 to 12 carbon atoms or R1, R2 and R3 are each independently —(CH2)k—COOR4 where k is 0, 1 or 2 and R4 is hydrogen or straight or branched chain alkyl of 1 to 20 carbon atoms. The mixtures of formula I and II are liquid at ambient conditions and are effective stabilizers for polyolefins.

Abstract: The invention provides, inter alia, novel bisphosphonate compounds and methods of making and using. In embodiments, the invention provides compounds and methods in connection with research and therapeutic applications, e.g., for tumor cell growth inhibition, activation of gammadelta T cells, inhibition of farnesyldiphosphate (FPPS) and/or undecaprenyldiphosphate synthase enzymes, bone resorption diseases, cancer, immune disorders, immunotherapy, and infectious diseases. In regards to certain embodiments, a surprising advance has been the recognition that certain structural features can significantly enhance the activity of the compounds. For example, the presence of particular cationic species e.g., phosphonium, sulfonium, and arsonium moieties can contribute to desirable functional activity when positioned near a bisphosphonate moiety. In other embodiments of non-nitrogen containing bisphosphonates, terphenyl and benzyl bisphosphonate compounds and methods are provided. Further variations are also provided.

Abstract: The invention provides compounds comprising at least one phosphohalohydrin group of the formula: where X is a halogen selected from among I, Br, Cl, R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, and n is an integer between 2 and 20, processes for the production thereof and uses theroef, in particular therapeutic uses and for activating primate T?9?2 lymphocytes.

Abstract: Disclosed are new compositions consisting of polyphosphonates and specific additive compositions that exhibit superior resistance to degradation due to exposure to air, high temperature and air, moisture or combinations thereof. Also disclosed are polymer mixtures or blends comprising these polyphosphonates/additive compositions and commodity and engineering plastics and articles produced therefrom. Further disclosed are articles of manufacture produced from these materials, such as fibers, films, coated substrates, moldings, foams, fiber-reinforced articles, or any combination thereof.

Abstract: The present invention relates to solid amorphous and crystalline forms of ibandronate sodium.

Abstract: The invention concerns the production of salts or chelates of methyl donors, in particular S-adenosyl-L-methionine or SAMe and betaine or N,N,N-trimethylglycine, with phytic acid or with phosphorylate inositol, possibly partially salified with metal cations, with the formation of stable, totally natural, compounds having a biological activity typical of the starting methyl donors and also combined with, and enhanced by, the biological activity typical of phytic acid or of inositol. The invention also concerns nutraceutical, pharmaceutical, dietary, phytopharmaceutical or veterinary compositions comrising one or more salts or complexes of methyl donors with phytic acid or its derivatives and the method for the synthesis thereof.

Abstract: A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (lOa-lOl) containing selected anions was achieved. Both the diphosphate sodium (lOa) and potassium salts (lOc) displayed aqueous solubility in excess of 220 mg/ml at room temperature and good cancer cell line inhibitory activity.

Abstract: The present invention concerns a process for hydrocyanating ethylenically unsaturated organic compounds to compounds containing at least one nitrile function. It relates more particularly to the hydrocyanation of diolefins such as butadiene or of substituted olefins such as alkenenitriles, for instance pentenenitriles. According to the process of the invention the reaction is implemented in the presence of a metal complex catalyst comprising a transition metal such as nickel and an organic ligand.

Abstract: The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultra-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. Said compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: A phosphate ester composition of low acidity achieved by treating the phosphate ester of high acidity with an oxetane compound. The phosphate ester can be represented by the formula (I), where Ar is an aryl or alkaryl group, R is an arylene or alkylene group, and n can range from to 0 to about 5.

Abstract: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.

Abstract: The present invention relates to an antiwear agent and lubricating compositions thereof. The invention further provides for a method of lubricating a driveline device or a grease application by employing a lubricating composition containing the antiwear agent.

Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.

Abstract: A system comprising a) Ni(0) b) from 4 to 10 mol per mol of Ni(0) in a) of a compound (I) of the formula P(X1R1)(X2R2)(X3R3) ??(I) where X1, X2, X3 are each, independently of one another, oxygen or a single bond, R1, R2, R3 are, independently of one another, identical or different organic radicals and c) from 1 to 4 mol per mol of Ni(0) in a) of a compound (II) of the formula where X11, X12, X13 X21, X22, X23 are each, independently of one another, oxygen or a single bond, R11, R12 are identical or different, individual or bridged organic radicals, R21, R22 are identical or different, individual or bridged organic radicals and Y is a bridging group is suitable as catalyst for preparing mixtures of monoolefinic C5 mononitriles having nonconjugated C?C and C?N bonds by hydrocyanation of a 1,3-butadiene-containing hydrocarbon mixture and for preparing a dinitrile by hydrocyanation of a mixture of monoolefinic C5 mononitriles having nonconjugated C?C and C?N bonds.

Abstract: The present invention concerns a process for hydrocyanating ethylenically unsaturated organic compounds to compounds containing at least one nitrile function. It relates more particularly to the hydrocyanation of diolefins such as butadiene or of substituted olefins such as alkenenitriles, for instance pentenenitriles. According to the process of the invention the reaction is implemented in the presence of a metal complex catalyst comprising a transition metal such as nickel and an organic ligand.

Abstract: The invention relates to the use of alkoxyamines of formula (I): for the preparation of polymerized or non-polymerized mono- or polyalkoxyamines of formula (II):

Abstract: Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1–C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl.

Abstract: The invention provides compounds comprising at least one phosphoepoxide group of the formula: where R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate T?9?2 lymphocytes.

Abstract: The invention relates to phosphinites I of formulae (1) or (2), in which R1, R2, R5, R6, R7, R8, R9 independently represent hydrogen, an alkyl or alkylene group having 1 to 8 carbon atoms or an alkoxy group having 1 to 8 carbon atoms; R3 is H or methyl; R4 is i-propyl or t-butyl; X is F, Cl or CF3 and n is 1 or 2

Abstract: The present invention relates to derivatives of 1-hydroxymethylene-1,1-bisphosphonic acid, the pharmaceutical compositions comprising them, and their application in therapeutics, particularly for the treatment of cancerous tumors. It is also directed to a methods of preparation of such derivatives.

Abstract: A bis(aminostyryl)naphthalene compound represented by the general formula [I] or the like below. General Formula [I] (where R2 and R3 each denotes an unsubstituted aryl group; R1 and R4 each denotes an aryl group having a specific substituent such as methoxy group; and R5 and R6 each denotes a cyano group or the like.) A process for producing a bis(aminostyryl)naphthalene compound represented by the general formula [I] by condensation of, for example, 4-(N,N-diarylamino)benzaldehyde with diphosphonic ester or diphosphonium. The bis(aminostyryl)naphthalene compound emits intense yellow or red light. The process permits efficient production of the bis(aminostyryl)naphthalene compound.

Abstract: The invention relates to polymeric phosphinic acids and their salts of the formula (I) 1

Abstract: Inositol derivatives, compositions comprising inositol derivatives, and methods for using compositions comprising inositol derivatives as agents for activating the secretion of chloride ions and/or treatment of inflammation are described.

Abstract: A derivative of phosphoric acid ester salt or adduct or a mixture thereof is obtained from a reaction product, polycondensed with at least one aldehyde, of at least one polyol phosphoric acid ester with at least one organic nitrogen base. The derivative is advantageously used as a flame-inhibiting and/or intumescent treatment in plastic mouldings, on porous carriers or in paint or coating systems. The production of the derivative or a mixture thereof by reacting at least one polyol with phosphorus pentoxide and reacting the polyol phosphoric acid ester obtained in that way with at least one organic nitrogen base forming a phosphoric acid ester salt or adduct, is characterised in that the amount of phosphorus pentoxide required for the esterification operation is suspended in an amount of the ester or ester mixture to be produced, then at a temperature in the range of 20-180° C.

Abstract: A novel antioxidant has the advantages of both the hindered phenols and the phosphite antioxidant is prepared from phosphorus trichloride and 2,5-di-tert-butylhydroquinone, such as tetrakis-(2,5-di-tert-butyl-4-hydroxyphenyl)-2,5-di-tert-butyl-hydroquinonediyl diphosphite.

Abstract: The present invention provides an acrylophosphate derivatives of the formula (I) wherein n≧1; Ar is or The acrylophosphate derivatives of formula (I) have high char residue test results by TGA.

Abstract: A novel class of compounds, i.e., 1,1-bis-H-phosphinates (or 1,1-bis-H-phosphinic acid derivatives) are provided. Also provided are novel methods for producing 1,1-bis-H-phosphinates and 1,1-bis-H-phosphinate conjugates. These compounds and conjugates are used as precursors of bisphosphonates and bisphosphonate conjugates, respectively, or as prodrugs directly for treating bone-related and various other diseases.